### In Focus channel feed ### [Can AI do scientific research? Billions are pouring in to find out](https://endpoints.news/can-ai-do-scientific-research-billions-chase-hopes-of-superintelligence/ "Can AI do scientific research? Billions are pouring in to find out") 3 weeks ago [AI](https://endpoints.news/channel/ai/ "Channel: AI") ### [Fetal gene therapy inches closer. Will embryo editing follow?](https://endpoints.news/fetal-gene-therapys-progress-calls-into-question-the-taboo-on-embryo-editing/ "Fetal gene therapy inches closer. Will embryo editing follow?") 4 weeks ago [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") ### [Bristol Myers reaches a crossroads as a make-or-break year takes shape](https://endpoints.news/bristol-myers-reaches-a-crossroads-as-a-make-or-break-year-takes-shape/ "Bristol Myers reaches a crossroads as a make-or-break year takes shape") Last month [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") ### [Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy](https://endpoints.news/exclusive-uc-berkeley-startup-bets-on-jumping-genes-for-glp-1-gene-therapy/ "Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy") Last month [Cell/Gene Tx](https://endpoints.news/channel/cell-gene-tx/ "Channel: Cell/Gene Tx") ### [Novartis built a big business around delivering radioactive cancer treatments. Can a generic compete?](https://endpoints.news/novartis-radioligand-therapy-lutathera-could-soon-face-generic-competition/ "Novartis built a big business around delivering radioactive cancer treatments. Can a generic compete?") Last month [Pharma](https://endpoints.news/channel/pharma/ "Channel: Pharma") ### [How pharma is capitalizing on the sudden revival and success of an old asthma drug](https://endpoints.news/how-a-20-year-old-asthma-drug-is-boosting-food-allergy-research/ "How pharma is capitalizing on the sudden revival and success of an old asthma drug") 2 months ago [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") ### [A simpler, single-strand form of DNA may be key to non-viral gene therapy, study suggests](https://endpoints.news/a-simpler-form-of-dna-may-be-key-to-non-viral-gene-therapy-study-suggests/ "A simpler, single-strand form of DNA may be key to non-viral gene therapy, study suggests") 3 months ago [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") ### [How GLP-1 weight loss compounders reshaped the drug industry](https://endpoints.news/compounders-prescribing-glp-1s-put-pricing-pressure-on-novo-lilly/ "How GLP-1 weight loss compounders reshaped the drug industry") 3 months ago [Health Tech](https://endpoints.news/channel/health-tech/ "Channel: Health Tech") ### [After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there](https://endpoints.news/eli-lilly-ceo-david-ricks-seeks-exit-velocity-for-pharmas-future/ "After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there") 3 months ago [Pharma](https://endpoints.news/channel/pharma/ "Channel: Pharma") ### [Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans](https://endpoints.news/china-is-taking-on-the-worlds-10-most-expensive-medicines/ "Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans") 3 months ago [China](https://endpoints.news/channel/china/ "Channel: China") ### [Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future](https://endpoints.news/novo-nordisks-strategic-conundrum-how-being-anchored-to-the-past-could-cost-it-the-future/ "Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future") 3 months ago [Pharma](https://endpoints.news/channel/pharma/ "Channel: Pharma") ### [Exclusive: First test of gene therapy for rare form of autism is underway](https://endpoints.news/first-test-of-gene-therapy-for-rare-form-of-autism-is-underway/ "Exclusive: First test of gene therapy for rare form of autism is underway") 3 months ago [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") ### [More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem](https://endpoints.news/how-a-closet-full-of-ekg-machines-illustrates-pharmas-clinical-trial-cost-problem/ "More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem") 4 months ago [Pharma](https://endpoints.news/channel/pharma/ "Channel: Pharma") ### [Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters](https://endpoints.news/hengrui-blazes-trail-as-chinese-drugmakers-aspire-to-go-multinational/ "Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters") 4 months ago [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") ### [Gene editing's search for a 'holy grail' has led to an explosion of tools, but few cures](https://endpoints.news/as-gene-editing-tools-multiply-the-hunt-for-the-final-technology-continues/ "Gene editing's search for a 'holy grail' has led to an explosion of tools, but few cures") 5 months ago [Cell/Gene Tx](https://endpoints.news/channel/cell-gene-tx/ "Channel: Cell/Gene Tx") ### [The Endpoints winners and losers list: Who was up and who was down in 2025](https://endpoints.news/biopharmas-winners-and-losers-of-2025/ "The Endpoints winners and losers list: Who was up and who was down in 2025") 5 months ago ### [Models are out, molecules are in as AI startups sprint to clinic](https://endpoints.news/ai-biotech-preview-of-2026-clinic-takes-center-stage/ "Models are out, molecules are in as AI startups sprint to clinic") 6 months ago [AI](https://endpoints.news/channel/ai/ "Channel: AI") ### [China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in](https://endpoints.news/western-genetic-medicine-makers-turn-to-chinese-investigator-initiated-trials/ "China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in") 6 months ago [China](https://endpoints.news/channel/china/ "Channel: China") ### [As approval date looms, Cytokinetics gears up for David-and-Goliath battle with Bristol Myers](https://endpoints.news/as-approval-date-looms-cytokinetics-gears-up-for-david-and-goliath-battle-against-bristol-myers/ "As approval date looms, Cytokinetics gears up for David-and-Goliath battle with Bristol Myers") 6 months ago [Pharma](https://endpoints.news/channel/pharma/ "Channel: Pharma") ### [Are recent strides in neurology R&D enough to make it a hot M&A target?](https://endpoints.news/are-recent-strides-in-neurology-rd-enough-to-make-it-a-hot-ma-target/ "Are recent strides in neurology R&D enough to make it a hot M&A target?") 7 months ago [Deals](https://endpoints.news/channel/deals/ "Channel: Deals") ### [Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?](https://endpoints.news/are-pd-1xvegf-bispecifics-being-tested-in-the-wrong-kinds-of-cancer/ "Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?") 8 months ago [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") ### [In China, a low-cost push to rival a life-saving, $2M medicine](https://endpoints.news/chinese-biotechs-work-on-cheaper-alternatives-to-2m-zolgensma/ "In China, a low-cost push to rival a life-saving, $2M medicine") 8 months ago [China](https://endpoints.news/channel/china/ "Channel: China") ### [David Reese bets his career on the 'hinge moment' for AI at Amgen](https://endpoints.news/in-the-lab-how-amgen-sees-ai-changing-pharma-rd/ "David Reese bets his career on the 'hinge moment' for AI at Amgen") 8 months ago [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") ### [Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss](https://endpoints.news/biopharma-returns-to-mc4r-for-drugs-targeting-genetic-obesity-as-well-as-appetite-loss/ "Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss") 9 months ago [R&D](https://endpoints.news/channel/rd/ "Channel: R&D") [Pharma](https://endpoints.news/channel/pharma/ "Channel: Pharma")